BriaCell Secures License for a Promising Novel Anti-Cancer Agent
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 04, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...
Cancer
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
MINNEAPOLIS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...
Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
Clinical Trial Now Expands to Fifteen U.S. Trial SitesHOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX),...
SAB Biotherapeutics to Host Virtual 2022 Annual R&D Portfolio Update
SIOUX FALLS, S.D., Aug. 04, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage biopharmaceutical company with a first...
Biofrontera Inc. to Report Second Quarter Financial Results on August 12, 2022
WOBURN, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
– CFT7455, a Novel IKZF1/3 Degrader, Advancing Through Dose Escalation Portion of Phase 1/2 Clinical Trial – – Phase 1/2 Clinical...
Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results
ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics...
Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights
– MGTA-117 Phase 1/2 clinical trial progress continues and remains consistent with earlier observations of target binding, target cell reductions,...
PDS Biotech Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications
Safety evaluation of 43 patients with no grade 3 or higher treatment-related adverse eventsFLORHAM PARK, N.J., Aug. 04, 2022 (GLOBE...
Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster
Single ascending dose (SAD) Phase 1 Study completed in Australia with a maximum dose of 2,000 mg.Pharmacokinetics (PK) were dose...
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering...
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™
Nes-Ziona, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
EDAP TMS SA to Announce Second Quarter 2022 Financial Results on August 24th, 2022
Company to host conference call and webcast on Thursday, August 25that 8:30 am EDT LYON, France, August 3, 2022 -...
CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of...
Mersana Therapeutics to Host Second Quarter 2022 Conference Call on August 8, 2022 and Present at Upcoming Conferences
CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...
Black Diamond Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference
CAMBRIDGE, Mass. and NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology...
Y-mAbs to Announce Second Quarter 2022 Financial and Operating Results on August 8, 2022
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that...
G1 Therapeutics to Participate Virtually in the 2022 BTIG Biotechnology Conference and the 2022 Wedbush Pacgrow Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...
Novel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirus
ProLectin-M, a new class of oral antiviral drug BOSTON, MASSACHUSETTS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (Symbol: BIXT)...
Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model
CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on...